Phospho-EPHA3 (Tyr779/833) Antibody

What is the functional significance of EPHA3 phosphorylation at Tyr779/833?

Tyrosine phosphorylation at positions 779 and 833 represents critical regulatory sites in EPHA3 receptor signaling. Studies have demonstrated that Y779 is one of the major phosphorylation sites in the EPHA3 receptor, alongside Y596 and Y602 . While Y596 phosphorylation is essential for the initial activation of EPHA3 kinase activity, Y779 phosphorylation serves distinct downstream signaling functions.

Specifically, Y779 has been identified as a key mediator in the activation of the small GTPase RhoA . This represents a functionally distinct pathway from Y602, which is primarily involved in ERK inhibition. The phosphorylation state of Y779 significantly impacts the ability of EPHA3 to regulate cell migration, as mutation studies have shown that Y779F mutations partially reduce EPHA3-mediated inhibition of cell migration by approximately half compared to wild-type receptor function .

How does phosphorylation at Tyr779 collaborate with other phosphotyrosine residues?

The functional activity of EPHA3 depends on collaborative interactions between multiple phosphotyrosine residues. Research has demonstrated that Y779 works in concert with Y602 to produce full EPHA3-mediated biological responses . This cooperative relationship is particularly evident in cell migration studies.

Interestingly, while Y779 and Y602 collaborate in migration regulation, they mediate distinct downstream signaling events. Y602 is specifically required for EPHA3-mediated inhibition of ERK phosphorylation, while Y779 is dispensable for this function . Conversely, Y779 plays a critical role in RhoA activation, representing a separate signaling branch. This functional separation with collaborative outcomes highlights the sophisticated signaling network downstream of EPHA3 activation.

How is EPHA3 phosphorylation regulated under normal physiological conditions?

EPHA3 phosphorylation is regulated through a dynamic balance between kinase and phosphatase activities. Under normal physiological conditions, EPHA3 activation is triggered by binding to ephrin ligands (particularly EFNA5) residing on adjacent cells, leading to receptor clustering and autophosphorylation .

The phosphorylation state of EPHA3 is actively maintained through opposing enzymatic activities:

• Autophosphorylation: Upon ephrin binding, EPHA3 undergoes autophosphorylation at multiple tyrosine residues, including Y596, Y602, and Y779 . The phosphorylation of Y596 in the juxtamembrane region is particularly critical, as it relieves autoinhibition and permits full kinase activation.

• Dephosphorylation: Protein tyrosine phosphatases (PTPs) actively counterbalance EPHA3 phosphorylation. Research has identified PTPN1 (PTP1B) as a specific phosphatase that dephosphorylates EPHA3 . Studies with leukemia cell lines (LK63) have demonstrated that elevated phosphatase activity can substantially reduce EPHA3 phosphorylation levels even when the receptor possesses intrinsic kinase activity .

Experimental evidence supports this dynamic regulation. When EPHA3 from ephrin-stimulated cells was exposed to cell lysates with high phosphatase activity, phosphorylation levels decreased dramatically . Conversely, exposing under-phosphorylated EPHA3 to lysates with normal phosphatase levels resulted in increased phosphorylation . This balance is likely cell-type specific and may be altered in pathological conditions.

What are the optimal applications for Phospho-EPHA3 (Tyr779/833) antibodies?

Phospho-EPHA3 (Tyr779/833) antibodies are valuable tools for studying the activation state of EPHA3 receptors. Based on manufacturer specifications and research applications, these antibodies can be effectively utilized in several experimental techniques:

• Immunohistochemistry (IHC): Recommended dilution ranges from 1:50-1:300 . This application allows for in situ detection of phosphorylated EPHA3 in tissue sections, enabling visualization of receptor activation patterns in physiological contexts.

• Immunofluorescence (IF): Optimal dilution range of 1:50-1:200 . This technique provides cellular resolution of receptor phosphorylation status and allows co-localization studies with other proteins of interest.

• Enzyme-Linked Immunosorbent Assay (ELISA): Recommended at higher dilutions of 1:1000-1:10000 . This application is suitable for quantitative assessment of phosphorylated EPHA3 levels in cell or tissue lysates.

• Western Blotting: While not explicitly mentioned for all antibody products, Western blotting has been successfully employed in research studies to detect phosphorylated EPHA3 at approximately 110kDa . This application is particularly valuable for assessing changes in phosphorylation levels under different experimental conditions.

It's important to note that these antibodies detect endogenous levels of EPHA3/4/5 only when phosphorylated at Tyr779/833 , making them specific for the activated form of the receptor. The cross-reactivity with EPHA4 and EPHA5 should be considered when interpreting results, as these receptors share conserved phosphorylation sites at equivalent positions.

What methods can be used to study the functional consequences of EPHA3 Tyr779 phosphorylation?

To investigate the specific functions of EPHA3 Tyr779 phosphorylation, researchers have employed several complementary methodologies:

• Site-directed mutagenesis: Replacing Tyr779 with phenylalanine (Y779F) prevents phosphorylation while maintaining structural similarity. This approach has been instrumental in determining the role of Y779 in various cellular functions . Alternative mutations like substituting tyrosine with glutamic acid (Y596E) have been used to mimic constitutive phosphorylation at other sites .

• Cell migration assays: Studies have utilized 293A cell line models to demonstrate that Y779F mutation partially reduces EPHA3-mediated inhibition of cell migration . These assays typically involve monitoring cell movement through transwell chambers or wound-healing assays following ephrin stimulation.

• Growth cone collapse assays: Hippocampal neurons have been used to assess how Y779 phosphorylation affects neuronal growth cone dynamics . This involves treating cultured neurons with ephrin ligands and quantifying growth cone collapse as a measure of EPHA3 signaling efficiency.

• RhoA activation assays: Since Y779 mediates RhoA activation, pull-down assays using the Rho-binding domain of Rhotekin coupled with Western blotting can quantify active RhoA levels in cells expressing wild-type versus Y779F mutant EPHA3 .

• Neurite outgrowth assays: NG108-15 neuronal cells have been employed to study how Y779 phosphorylation affects neurite extension, demonstrating that this site contributes to EPHA3-mediated reduction in neurite outgrowth .

When designing experiments to study Y779 phosphorylation, it's advisable to include appropriate controls such as kinase-dead mutants (K653R) and other tyrosine mutants (Y596F, Y602F) to differentiate site-specific effects from general disruption of kinase function .

How can I verify Phospho-EPHA3 (Tyr779/833) antibody specificity in my experimental system?

Ensuring antibody specificity is crucial for reliable data interpretation. For Phospho-EPHA3 (Tyr779/833) antibodies, consider implementing these validation approaches:

• Phosphatase treatment control: Treat one sample of your cell/tissue lysate with lambda phosphatase before immunoblotting. The phospho-specific signal should disappear in the treated sample while total EPHA3 levels (detected with a non-phospho-specific antibody) remain unchanged.

• Stimulation-dependent phosphorylation: Compare samples from unstimulated cells versus ephrin-A5 stimulated cells. Phospho-EPHA3 signals should increase significantly following ephrin stimulation, as demonstrated in various studies .

• Mutation controls: If possible, include lysates from cells expressing Y779F mutant EPHA3. This mutant should show reduced detection with the phospho-specific antibody compared to wild-type EPHA3 after ephrin stimulation .

• Peptide competition: Pre-incubate the antibody with the immunizing phosphopeptide before application to your samples. This should block specific binding and eliminate true phospho-EPHA3 signals.

• Cross-reactivity assessment: Since these antibodies may detect EPHA3, EPHA4, and EPHA5 when phosphorylated at equivalent sites, consider the expression profile of all three receptors in your experimental system. This is particularly important when interpreting results from tissues or cell lines that express multiple EphA receptors.

• ATP incubation test: For samples with low phosphorylation signals, isolate EPHA3 by immunoprecipitation and incubate with exogenous ATP as demonstrated in previous studies . This can confirm that the receptor is capable of phosphorylation even if endogenous phosphorylation is suppressed.

Remember that phospho-specific antibodies typically detect the protein only in its phosphorylated state, so changes in signal could reflect either changes in phosphorylation status or in total protein levels. Including parallel detection of total EPHA3 protein is recommended for comprehensive interpretation.

What is the relationship between EPHA3 Tyr779 phosphorylation and RhoA activation?

Tyrosine 779 phosphorylation of EPHA3 plays a critical and specific role in the activation of the small GTPase RhoA. Research has established a direct mechanistic link between this phosphorylation site and RhoA-mediated cytoskeletal responses. When EPHA3 is stimulated with ephrin-A5, wild-type receptors induce a significant increase (approximately 38%) in activated RhoA levels .

Mutation studies provide compelling evidence for the site-specific nature of this pathway. When Y779 is mutated to phenylalanine (Y779F), EPHA3-mediated RhoA activation is substantially reduced, while mutations of other tyrosine residues (except Y596 required for kinase activation) do not affect RhoA activation . This specificity indicates that Y779, when phosphorylated, likely serves as a docking site for adaptor proteins or RhoA guanine nucleotide exchange factors (GEFs) that directly promote RhoA activation.

The RhoA activation pathway mediated by phospho-Y779 appears to be functionally distinct from other EPHA3 signaling branches. For example, while Y602 is essential for EPHA3-mediated ERK inhibition, it does not significantly contribute to RhoA activation . This functional separation allows EPHA3 to coordinate multiple cellular responses through distinct phosphotyrosine-mediated signaling modules.

The Y779-RhoA signaling axis has significant implications for cytoskeletal dynamics, as RhoA is a master regulator of actin stress fiber formation and actomyosin contractility. This pathway likely underlies many of the morphological changes observed following EPHA3 activation, including growth cone collapse in neurons and reduced cell migration in other cell types .

How do phosphatase activities affect EPHA3 phosphorylation at Tyr779/833?

Protein tyrosine phosphatases (PTPs) play a critical regulatory role in modulating EPHA3 phosphorylation status, including at the Tyr779/833 sites. Research has revealed that elevated phosphatase activity can dramatically suppress EPHA3 phosphorylation even when the receptor possesses normal kinase function.

Studies with leukemia cell lines (LK63) demonstrated a striking phenomenon: despite having functional EPHA3 kinase (confirmed by in vitro kinase assays with exogenous ATP), these cells showed minimal receptor phosphorylation due to high endogenous phosphatase activity . When EPHA3 from these cells was exposed to lysates from cells with normal phosphatase levels, phosphorylation increased substantially. Conversely, when normally phosphorylated EPHA3 was incubated with lysates containing high phosphatase activity, phosphorylation levels decreased dramatically .

Among the phosphatases implicated in EPHA3 regulation, PTPN1 (also known as PTP1B) has been specifically identified as capable of dephosphorylating EPHA3 . Other studies have suggested roles for additional phosphatases in regulating Eph receptor signaling, creating a complex regulatory network.

The dynamic interplay between kinase and phosphatase activities has important implications for research:

• Cell type-specific variations in phosphatase activity may result in different baseline levels of EPHA3 phosphorylation.

• Phosphatase inhibitors may be necessary to detect phosphorylation in experimental systems with high phosphatase activity.

• Changes in phosphatase expression or activity in pathological conditions could alter EPHA3 signaling independent of receptor expression or ligand availability.

When investigating EPHA3 phosphorylation at Y779/833, researchers should consider including phosphatase inhibitors in lysis buffers and potentially examine the expression/activity levels of relevant phosphatases in their experimental system.

What are the differences in signaling outcomes between Tyr779 and other phosphorylation sites on EPHA3?

Key functional distinctions include:

Understanding these distinctions is crucial for designing targeted interventions that modulate specific aspects of EPHA3 signaling without disrupting the entire signaling network.

Why might I observe low or absent phospho-EPHA3 (Tyr779/833) signal despite high receptor expression?

Several factors can contribute to low phospho-EPHA3 signal despite substantial receptor expression. Understanding and addressing these issues is crucial for successful experimental outcomes:

If these approaches don't resolve the issue, an in vitro kinase assay can determine whether the receptor maintains kinase potential despite showing low phosphorylation in cellular contexts .

How can I distinguish between EPHA3, EPHA4, and EPHA5 phosphorylation using commercial antibodies?

Distinguishing between phosphorylated EPHA3, EPHA4, and EPHA5 presents a significant challenge due to sequence homology around the Tyr779/833 region. Most commercial phospho-specific antibodies, including those described in the search results, recognize the phosphorylated forms of all three receptors . Here are methodological approaches to achieve receptor specificity:

• Sequential immunoprecipitation: First, use receptor-specific antibodies to immunoprecipitate EPHA3, EPHA4, or EPHA5 individually, then probe with the phospho-specific antibody. This approach allows determination of phosphorylation status for each receptor separately.

• Receptor-specific knockdown/knockout: Use siRNA knockdown or CRISPR-Cas9 knockout of individual Eph receptors, then assess changes in phospho-signal. The reduction in signal after EPHA3 knockdown, for example, would represent the EPHA3-specific component.

• Heterologous expression systems: Transfect receptor-negative cell lines with individual Eph receptors and assess phosphorylation. This approach was utilized in studies with 293A cells expressing wild-type or mutant EPHA3 .

• Receptor-specific immunoprecipitation with phosphotyrosine blotting: Immunoprecipitate specific Eph receptors using receptor-specific antibodies, then blot with general anti-phosphotyrosine antibodies (e.g., 4G10 or PY20). This approach avoids cross-reactivity issues of phospho-specific antibodies.

• Mass spectrometry analysis: For definitive identification, immunoprecipitate individual Eph receptors and analyze phosphopeptides by mass spectrometry. This can precisely identify which phosphorylation sites are occupied on which receptor.

• Expression pattern analysis: In some experimental systems, one receptor may predominate. Assess relative expression levels of EPHA3, EPHA4, and EPHA5 in your model system to determine which receptor likely contributes most to the observed phospho-signal.

It's important to recognize that the sequence similarity that results in antibody cross-reactivity also suggests functional conservation. The equivalent tyrosine residues in EPHA3, EPHA4, and EPHA5 may serve similar signaling functions across these receptors.

What are the critical controls for experiments investigating EPHA3 Tyr779 phosphorylation?

Robust experimental design requires appropriate controls to ensure reliable interpretation of results related to EPHA3 Tyr779 phosphorylation. Based on published research methodologies, the following controls are recommended:

• Stimulation controls:

  • Unstimulated cells (negative control)

  • Ephrin-A5 stimulated cells (positive control)

  • Time-course of stimulation (typically 5, 15, 30 minutes)

• Mutation controls:

  • Kinase-dead mutant (K653R) - Should show no phosphorylation at any tyrosine residue

  • Y596F mutant - Should show no phosphorylation due to lack of kinase activation

  • Y779F mutant - Should show normal phosphorylation at other sites but not at position 779

  • Y602F mutant - Should show normal phosphorylation patterns but altered downstream signaling

• Phosphatase controls:

  • Phosphatase inhibitor treatment - Should enhance phosphorylation signals

  • In vitro phosphatase treatment of samples - Should eliminate phospho-specific signals

  • ATP incubation of immunoprecipitated EPHA3 - Can reveal kinase potential even when cellular phosphorylation is suppressed

• Antibody specificity controls:

  • Peptide competition - Pre-incubation with immunizing phosphopeptide should block specific signals

  • Parallel blotting with phospho-specific and total EPHA3 antibodies - Differentiates changes in phosphorylation from changes in expression

  • Secondary antibody-only control - Eliminates false positives from non-specific secondary antibody binding

• Functional outcome controls:

  • When studying Y779-dependent functions (e.g., RhoA activation), include:

    • RhoA inhibitor treatment (e.g., C3 transferase)

    • Constitutively active RhoA expression

    • Dominant-negative RhoA expression

• Cell type controls:

  • Cell lines with known EPHA3 expression and phosphorylation responses

  • Cell lines lacking EPHA3 expression as negative controls

When examining downstream effects of Y779 phosphorylation, it's advisable to include measurements of both immediate signaling events (RhoA activation) and ultimate biological outcomes (migration, growth cone collapse) to establish functional connectivity between the phosphorylation event and cellular responses .

How can phospho-EPHA3 (Tyr779/833) detection be applied in cancer research?

EPHA3 has emerged as a significant factor in cancer biology, with phosphorylation at Tyr779/833 potentially serving as both a biomarker and therapeutic target. Several applications for phospho-EPHA3 detection in cancer research have been identified:

• Biomarker development: EPHA3 has been identified as a tumor antigen targeted by lytic CD4 T-cells , suggesting its potential as an immunotherapy target. Phosphorylation status at Y779/833 could provide information about receptor activation in patient samples, potentially correlating with disease progression or treatment response.

• Cellular signaling analysis: Studies in colorectal cancer cell lines (LS174T and DLD1) have investigated EPHA3 signaling . While these particular studies did not show effects on proliferation, phosphorylation status at Y779 could be relevant to other cancer-related processes like migration, invasion, or angiogenesis given its role in RhoA activation.

• Drug response prediction: Since Y779 phosphorylation mediates specific downstream pathways, its status might predict responsiveness to targeted therapies that affect RhoA signaling or cytoskeletal dynamics.

• Mutation impact assessment: Many cancers harbor mutations in EPHA3. Phospho-specific antibodies can help determine how these mutations affect receptor activation. For example, researchers could investigate whether the compound heterozygous mutations (T719I and M847K) in DLD1 cells alter Y779 phosphorylation patterns .

• Therapeutic targeting: Understanding the specific consequences of Y779 phosphorylation could guide development of targeted interventions that block this specific signaling branch without disrupting other EPHA3 functions, potentially reducing side effects.

• Resistance mechanisms: In cancer cells with elevated phosphatase activity, EPHA3 signaling might be suppressed despite receptor expression . Phospho-specific detection could identify tumors with this phenotype, potentially guiding combination therapies with phosphatase inhibitors.

As research progresses, phospho-EPHA3 detection may become increasingly valuable in stratifying patients for targeted therapies and monitoring treatment efficacy in real-time.

What are the emerging techniques for studying phosphorylation dynamics of EPHA3 at Tyr779?

Recent technological advancements have expanded the methodological toolkit available for investigating EPHA3 phosphorylation dynamics at Tyr779 with improved temporal and spatial resolution:

• FRET-based phosphorylation sensors: Genetically encoded Förster resonance energy transfer (FRET) sensors can be designed to monitor EPHA3 phosphorylation in real-time in living cells. These typically consist of EPHA3 sandwiched between fluorescent proteins, with a phosphotyrosine-binding domain that changes conformation upon phosphorylation.

• Phosphoproteomics with targeted mass spectrometry: Selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) mass spectrometry approaches enable quantitative tracking of specific phosphopeptides containing Tyr779 across multiple experimental conditions or time points.

• Phospho-specific nanobodies: Single-domain antibody fragments can be developed with specificity for phosphorylated Tyr779 and conjugated to fluorescent proteins for live-cell imaging of phosphorylation dynamics.

• Proximity ligation assays (PLA): This technique can detect phosphorylated EPHA3 with spatial resolution in fixed samples by using antibodies against EPHA3 and phosphotyrosine, producing a fluorescent signal only when the two epitopes are in close proximity.

• Optogenetic control of EPHA3 clustering: Light-inducible clustering systems can trigger EPHA3 activation with precise temporal control, allowing detailed investigation of the kinetics of Tyr779 phosphorylation and subsequent signaling events.

• CRISPR-mediated endogenous tagging: Knock-in of epitope tags or fluorescent proteins at the endogenous EPHA3 locus enables study of phosphorylation dynamics at physiological expression levels.

• Single-molecule tracking: This approach can examine how Tyr779 phosphorylation affects EPHA3 lateral mobility, clustering, and interactions with other membrane proteins.

• Quantitative phosphoproteomics with isobaric labeling: Techniques such as TMT (tandem mass tag) labeling enable multiplexed analysis of phosphorylation changes across multiple conditions or time points, providing a systems-level view of how EPHA3 phosphorylation at Tyr779 fits into broader signaling networks.

These emerging techniques promise to provide unprecedented insights into the spatiotemporal dynamics of EPHA3 phosphorylation, potentially revealing new aspects of its regulation and function in both physiological and pathological contexts.

How might understanding EPHA3 Tyr779 phosphorylation contribute to therapeutic development?

The detailed characterization of EPHA3 Tyr779 phosphorylation and its specific signaling consequences opens several avenues for therapeutic innovation:

• Targeted pathway inhibition: Since Y779 specifically mediates RhoA activation without affecting other EPHA3 functions like ERK inhibition , drugs targeting this specific signaling branch could modulate cytoskeletal dynamics without disrupting other EPHA3 functions. This selective approach could potentially reduce side effects compared to general EPHA3 inhibition.

• Rational combination therapies: Understanding that Y779 and Y602 phosphorylation mediate parallel but complementary pathways that contribute to cell migration inhibition suggests that therapeutic strategies targeting both pathways simultaneously might produce synergistic effects. This could inform rational drug combinations in cancer treatment.

• Phosphorylation-state specific antibodies: Therapeutic antibodies could be developed that specifically recognize and modulate EPHA3 when phosphorylated at Y779. Such antibodies might either block downstream signaling from this site or trigger receptor internalization and degradation.

• Phosphatase modulation: Research demonstrating that protein tyrosine phosphatases actively counterbalance EPHA3 phosphorylation suggests that phosphatase inhibitors could enhance EPHA3 signaling in contexts where this would be beneficial, such as in tumors where EPHA3 acts as a tumor suppressor.

• Predictive biomarkers: Y779 phosphorylation status could serve as a biomarker to predict responsiveness to therapies targeting EPHA3 or its downstream pathways. This could enable patient stratification for clinical trials and personalized treatment approaches.

• Scaffold disruptors: Small molecules or peptides could be designed to disrupt the interaction between phosphorylated Y779 and its downstream effectors, providing another mechanism to selectively inhibit this signaling branch.

• Cell-based therapies: The finding that EPHA3 is a tumor antigen recognized by CD4 T-cells suggests potential for immunotherapies directed against cells with high levels of EPHA3 expression or activation. Monitoring Y779 phosphorylation could help identify suitable patients for such approaches.

As our understanding of the structural basis and dynamics of Y779 phosphorylation continues to evolve, additional therapeutic strategies will likely emerge, particularly in areas like neurodevelopmental disorders, cancer, and inflammatory conditions where EPHA3 signaling plays important roles.